



an Open Access Journal by MDPI

## WAMD: From Pathophysiology to Therapeutic Approaches Treatment

Guest Editors:

### Dr. Enzo Maria Vingolo

Department of Medical-Surgical Sciences and Biotechnologies, U.O.C. Ophthalmology, Sapienza University of Rome, Via Firenze 1, 04019 Terracina, Italy

### Dr. Stefano Lupo

Department of Medical-Surgical Sciences and Biotechnologies, U.O.C. Ophthalmology, Sapienza University of Rome, Via Firenze 1, 04019 Terracina, Italy

### Dr. Francesca Toja

Department of Medical-Surgical Sciences and Biotechnologies, U.O.C. Ophthalmology, Sapienza University of Rome, Via Firenze 1, 04019 Terracina, Italy

Deadline for manuscript submissions:

**closed (30 April 2022)**



[mdpi.com/si/50968](https://mdpi.com/si/50968)

### Message from the Guest Editors

Dear Colleagues,

In this Special Issue on wet age-related macular degeneration (wAMD), we would like to explore new wAMD strategies to achieve better visual acuity and retina structural outcomes. Age-related macular degeneration is one of the main causes of visual impairment in elderly people. While the dry form has no approved treatment, several therapies have been proposed for the wAMD form to try to change the course of the disease and to improve visual acuity. The main treatments for wAMD are based on targeting choroidal neovascular membranes. The anti-VEGF agents have dramatically improved the disease outcome. In this issue, we are especially interested in examining consolidated and new anti-VEGF therapies and also considering the treatment protocols. Potential topics will include:

- Aflibercept, ranibizumab and brolucizumab treatment regimen
- Clinical trials for new drugs development
- Different types of wAMD and related disease outcomes
- Possible application of telemedicine in wAMD diagnosis and follow-up
- Nutritional supplements in wAMD

Dr. Enzo Maria Vingolo

Dr. Stefano Lupo

Dr. Francesca Toja

*Guest Editors*

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI